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Abstract
Background: The World Health Organization’s End Tuberculosis Strategy states that no tuberculosis (TB)-affected
households should endure catastrophic costs due to TB. To achieve this target, it is essential to provide adequate
social protection. As only a few studies in many countries have evaluated social-protection programs to determine
whether the target is being reached, we assessed the effect of financial support on reducing the incidence of
catastrophic costs due to TB in Indonesia.
Methods: From July to September 2016, we interviewed adult patients receiving treatment for TB in 19 primary
health centres in urban, sub-urban and rural area of Indonesia, and those receiving multidrug-resistant (MDR) TB
treatment in an Indonesian national referral hospital. Based on the needs assessment, we developed eight scenarios
for financial support. We assessed the effect of each simulated scenario by measuring reductions in the incidence
of catastrophic costs.
Results: We analysed data of 282 TB and 64 MDR-TB patients. The incidences of catastrophic costs in affected
households were 36 and 83%, respectively. Patients’ primary needs for social protection were financial support to
cover costs related to income loss, transportation, and food supplements. The optimum scenario, in which financial
support would be provided for these three items, would reduce the respective incidences of catastrophic costs in
TB and MDR-TB-affected households to 11 and 23%. The patients experiencing catastrophic costs in this scenario
would, however, have to pay high remaining costs (median of USD 910; [interquartile range (IQR) 662] in the TB
group, and USD 2613; [IQR 3442] in the MDR-TB group).
Conclusions: Indonesia’s current level of social protection is not sufficient to mitigate the socioeconomic impact of
TB. Financial support for income loss, transportation costs, and food-supplement costs will substantially reduce the
incidence of catastrophic costs, but financial support alone will not be sufficient to achieve the target of 0% TB-
affected households facing catastrophic costs. This would require innovative social-protection policies and higher
levels of domestic and external funding.
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Background
Poverty is closely related to tuberculosis (TB), both as
a risk and as an effect. People in low-income house-
holds not only have a higher risk of TB infection, but
once they are infected, the high costs associated with
diagnosis and treatment may reduce them to poverty
[1, 2]. Although almost all countries provide drugs
free of charge to patients with susceptible TB and
multidrug-resistant TB (MDR-TB), TB patients still
face high direct non-medical costs such as those for
travel, food, and nutritional supplements [3–5].
Indonesia has the world’s third largest number of esti-
mated TB cases with the incidence of 842 000 (95%
Confidence Interval [CI] 767 000–919 000) cases. Des-
pite its free TB services, our recent study revealed
that the costs incurred during the treatment phase
constituted more than three-quarters of the total
costs [6]. These high costs can negatively affect treat-
ment adherence, clinical outcomes, and drop-out
rates, thereby further increasing future costs. The
high costs also carry the risk of plunging TB patients
and their families into poverty, or into even deeper
poverty for those already living in poverty [7–11].
In response to this socioeconomic burden, the World
Health Organization’s (WHO’s) End TB Strategy aims by
2020 to reduce to zero the percentage of TB-affected
families that face catastrophic costs. Catastrophic costs
due to TB are defined as the total costs – i.e., all direct
and indirect costs, including income loss — that exceed
a specific threshold (e.g., 20%) of a household’s annual
income [12]. One obvious option for attaining this target
is by providing adequate social protection. In 2014, the
Indonesian government started a national health insur-
ance scheme that covers all the medical costs – includ-
ing those of TB treatment – incurred in primary,
secondary and tertiary healthcare. This scheme has sub-
stantially reduced direct medical costs. However, direct
medical costs are not the only costs patients face in the
trajectory from the pre-diagnostic phase to treatment
completion [4, 13]. In 2016, the previous study we con-
ducted in Indonesia showed that total costs consisted
largely of direct non-medical costs and income loss [6].
As these are not covered by the health insurance
scheme, TB patients are still at a high risk of facing cata-
strophic costs. This highlights the importance of provid-
ing additional financial protection to cover direct
non-medical costs and income loss [13].
There are three approaches to delivering additional so-
cial protection [14]. The first is the TB-specific
approach, which offers protection only to TB patients or
TB-affected households, for example by providing food--
supplements or travel vouchers to those undergoing TB
treatment in health facilities that are linked to the net-
work of the National Tuberculosis Program (NTP) [14,
15]. The second, the TB-inclusive approach, is a
broader intervention in which TB patients or
TB-affected households are one of the inclusion criteria
in a social-protection program. The third, the
TB-inclusive approach, involves protection policies that
do not explicitly include TB patients or TB-affected
families in their eligibility criteria but include TB
risk-reduction strategies for groups at a high risk for
TB infection, such as general cash transfers and
premium-free national health insurance for people in
poor households.
However, there is little evidence on the effectiveness
of financial protection (including cash transfers) in re-
ducing the incidence of catastrophic costs due to TB,
particularly in TB high-burden countries (HBCs). Al-
though recent studies have shown that cash transfers
could defray the costs endured by TB-affected house-
holds [15, 16], the transfers in question were either
given conditionally (on the basis of adherence to the
intervention program), or were given on the basis of
published national average cost data rather than of pa-
tients’ actual needs. There is limited evidence on the ef-
fect of social-protection schemes that take account of
patients’ needs and preferences [17].
In this study we therefore aimed to measure the so-
cioeconomic impact of TB and MDR-TB (including
the incidence of catastrophic costs), and to assess pa-
tients’ perceived needs for social protection in
Indonesia. Additionally, to assess the effects of finan-
cial support on the incidence of catastrophic costs
due to TB and MDR-TB in poor and non-poor
households, we developed and ran hypothetical sce-
narios in which patients were offered different combi-
nations of financial support.
Methods
Study design
To measure the socioeconomic impacts of TB and the
perceived needs for social protection, we interviewed TB
and MDR-TB patients. For TB patients, we applied
stratified clustered sampling in three districts of Java,
one representing an urban area of Indonesia (Jakarta),
one representing a suburban area (Depok), and one
representing a rural area (Tasikmalaya). In each district,
we randomly selected 5–8 primary health centres
(PHCs) that were linked with the Indonesian NTP.
Then, from July to September 2016, we selected con-
secutive TB patients consecutive TB patients as they reg-
istered at these PHCs. Assuming that the incidences of
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TB-affected household facing catastrophic costs were
20% (urban), 25% (suburban) and 30% (rural), assuming
a 1:1:1 ratio of TB incidence in urban, suburban and
rural district, and assuming a power of 0.80, we required
a minimum of 90 TB patients who met the inclusion cri-
teria in each district. We included adults aged 18 years
or above who had been diagnosed with TB and had ei-
ther received TB treatment for at least one month or
had finished the treatment no more than one month
previously. In this study, we focused on pulmonary TB
and excluded extra-pulmonary TB patients because of
potentially different seeking care pattern and costs. With
regard to MDR-TB, we interviewed adult patients who
had been diagnosed on the basis of GeneXpert® (Ce-
pheid, Sunnyvale, CA, USA) or sputum culture and had
been undergoing treatment for at least one month in
Persahabatan Hospital, an MDR-TB referral hospital in
Jakarta.
In both groups of patients, we assessed the follow-
ing variables: the incidence of catastrophic costs, the
socioeconomic impacts of TB or MDR-TB, and pa-
tients’ perceived needs for social protection. On the
basis of the needs assessment, we then developed sev-
eral scenarios for financial support. In each scenario,
we measured the reduction in the incidence of cata-
strophic costs after the hypothetical provision of fi-
nancial support.
Socioeconomic impacts due to TB and MDR-TB
To measure the socioeconomic impacts of TB, we used
the Tool to Estimate Patient Costs [12, 18], which we
adapted to the Indonesian context, also translating it to
Indonesian Bahasa. We recruited ten medical students
and public health graduates as interviewers and trained
them in the use of the adapted tool. We studied the inci-
dence of TB-affected households facing catastrophic costs;
patients’ perception of the their TB or MDR-TB is having
on their households’ financial capacity expressed on a
scale of 1–5, from no problem to a very serious problem;
coping strategy (loaning money or selling property); job
and income loss due to TB; and the proportional reduc-
tion in patients’ and households’ income. Patient and
household income loss were calculated both in absolute
terms (in United States dollars, USD) and in relative terms
(percentage of loss of previous income).
As well as collecting information on all types of cost (i.e.,
direct medical costs, direct non-medical costs, and indirect
costs) that had been incurred by the TB-affected house-
holds in the period between the pre-diagnostic phase and
treatment completion, we also collected information on
these households’ annual income. Following the latest
WHO protocol, we measured the incidence of catastrophic
costs (defined as total direct and indirect costs) that
exceeded 20% of each TB-affected household’s annual
income [6, 12]. Details of the methods we used to calculate
the incidence of catastrophic costs due to TB are provided
in our previous study [6].
Perceived needs for social protection
To assess patients’ knowledge of social protection and
their perceived needs for additional social protection, we
added three questions at the end of the adapted tool:
“Have you ever heard of social protection?”, followed by
an open question: “If yes, what is social protection? Can
you explain it?”
Patients’ answers were grouped according to six
types of social protection: general government aid for
the poor; government aid for healthcare; direct govern-
ment aid (general cash transfer); government aid for
education: government aid for transportation costs;
and other government aid. A patient’s inability to name
or explain any type of social protection was defined as
‘did not know’. These questions were important to our
ability to assess patients’ knowledge before questioning
them on their needs for social protection. After obtain-
ing the patients’ answers, the interviewers explained
the definition of social protection and gave examples
of several types of social-protection scheme [19]. They
then asked the patients whether they needed any social
protection, or additional protection if they already
receiving.
Patients who stated that they needed social protection
were asked to choose one cost item they wanted to be
covered, and its value in Indonesian Rupiahs (IDR). These
items comprised consultation fee per visit, transportation
costs per visit, food costs per visit, drug costs per month,
income loss per month, and food-supplement costs per
month. Food-supplement costs were defined as a patient’s
monthly spending on nutritional or food supplements
such as vitamins, fruits, milk, meats, or other nutritional
supplements that were consumed either with or without a
doctor’s TB-related recommendation [19]. After the pa-
tients’ answers had been obtained, the cost items that
needed to be covered were listed in order of priority (from
those that had been indicated most to those that had been
indicated least). The median (interquartile range [IQR]) of
these cost items was then calculated. In the scenarios that
we developed, we then used the median values of these
cost items as the value of financial support.
Effects of financial support
On the basis of the needs assessment, we selected the
three cost items that patients chose, and then developed
several hypothetical scenarios for financial support.
These comprised the following: no provision of a cash
transfer (baseline); the provision of a cash transfer to
cover a single cost item (i.e., income loss, transportation
costs, or food-supplementation); and the provision of a
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cash transfer to cover a combination of two or three cost
items. In total, we developed eight such scenarios. As well
as the baseline scenario (no cash transfers; Scenario I), we
formulated seven hypothetical cash-transfer scenarios for
the following: (II) transportation costs for all patients, (III)
food-supplement costs for all patients, (IV) income loss
for patients who had lost their jobs, (V) income loss for
patients who lost their income whether or not they had
lost their jobs, (VI) a combination of transportation costs
and income loss, (VII) a combination of food-supplement
costs and income loss, and (VIII) a combination of trans-
portation costs, food-supplement costs, and income loss.
We simulated the hypothetical scenarios in the people
who had been included in this study, assuming that the
cash transfers had been made after patients had started
TB or MDR-TB treatment. The value of the cash trans-
fer (CT) for specific cost items was extrapolated to a




CI identifies a specific cost item, i identifies the patient,
and h identifies his/her household). For transportation
costs, the total cash transfer was calculated by multiply-
ing CT by the number of PHC or hospital visits during
the intensive phase V
IP
i
and continuation phase V
CP
i
until the expected end date of treatment. For income
loss and food-supplement costs, the total value of the
cash transfer was calculated by multiplying CT by the
duration (in months) of the patients’ complete treat-
ment, M.
Box 1 Cash-transfers formula
Total CT transportation ¼P
i¼1
n
ððCTCI;hi x V IPi Þ þ ðCTCI;hi x VCPi ÞÞ








Total costs were defined as the sum of all types of
cost, including out-of-pocket payments (OOPs) for med-
ical diagnosis and treatment (OOPM); OOPs for
non-medical expenditures (OOPNM); and patients’ and
guardians’ income losses (IN). After calculating the total
simulated costs after the cash transfer (total costs for
TB-related services minus the total cash transfer), we es-
timated the incidence of catastrophic costs after the cash
transfer in each scenario. To define catastrophic costs,
we used the threshold of 20% of annual household in-
come (denoted τ TB ).
TB patient is denoted as j while the household is
denoted as i [12]. If there is more than one TB patient in
one household, costs for all patient within the household
will be collected or estimated. Although the hypothetical
scenarios were based on the optimistic assumption that
all patients would receive 100% of the potential cash
transfer, some intervention studies have shown that 10–
36% of targeted beneficiaries did not receive complete
financial support [15, 20, 21]. To obtain valid estimates
of the effect of the cash transfers, we ran sensitivity
analyses that assumed patients would receive 60, 70, 80,
and 90% of the potential cash transfer.
Data analysis
Data were entered into EpiInfo™ for Windows (Centers
for Disease Control and Prevention (CDC), Atlanta, GA,
USA) and Microsoft® Office Excel 2010 (Microsoft). For
data cleaning and analysis, we used IBM SPSS Statistics
for Windows, Version 21 (IBM Corp., Armonk, NY,
USA). Categorical variables were displayed as numbers
(n) and proportions (%). All costs, incomes, and values
of financial support for each cost item were collected in
IDR and then converted to US Dollars (USD) using the
average exchange rate by the World Bank for 2016 (USD
1 = IDR 13389.41) [22]. These numerical data were
abnormally distributed and therefore displayed as
median values (IQRs).
We compared the socioeconomic impacts, the
perceived needs for social protection, and the effect of
financial support between poor and non-poor households.
A poor household was defined as a household earning
below USD 1.9 per capita per day [23]. To compare the
socioeconomic impacts due to TB and the effects of finan-
cial support between poor and non-poor TB-affected
households, we applied generalized linear mixed models
with random effects to adjust for a cluster sampling design
(19 PHCs). For the MDR-TB group, we used chi-square,
Fisher, and Mann-Whitney tests to analyse the impacts
between poor and non-poor households. To compare the
effects of financial support between scenarios, we used
McNemar tests with stratification for cluster sampling for
TB (19 PHCs), and without stratification for MDR-TB.
For each scenario we used bootstrapping for internal vali-
dations of the incidence of catastrophic costs after cash
transfer and the average budget per patient required in
each scenario (N = 1000). The difference was considered
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Ethical statement
Ethical clearances for this study were obtained from the
Ethical Committee at the Faculty of Medicine of
Universitas Indonesia–Cipto Mangunkusumo Hospital,
Jakarta Indonesia (No. 416/UN2.F1/ETIK/VI/2016) and
the Ethical Committee at Persahabatan Hospital, Jakarta,
Indonesia (No. DL.01.03/II.3/3817/2016). We provided
written and oral explanations to patients before their
decision to sign the informed-consent form.
Results
In total, we analysed the data for 282 TB and 64
MDR-TB patients. The details of patients’ characteristics
are provided in our previous study on catastrophic costs
due to TB [6].
Socioeconomic impacts of TB or MDR-TB
The incidence of catastrophic costs due to TB was high,
and was significantly higher among MDR-TB-affected
households (83%) than among TB-affected ones (36%, P
< 0.001). Most MDR-TB patients (78%) perceived that
TB created moderate to severe problems for the finan-
cial capacity of their household. This proportion was
lower among TB patients (48%; P-value for the differ-
ence between MDR-TB and TB patients = 0.009). These
financial problems led more MDR-TB patients than TB
patients to loan money (50% vs 32%, P = 0.042) and to
sell property (28% vs 12%, P = 0.008) (see Table 1).
Among TB-affected households, poor households suf-
fered much more than non-poor households: they had a
higher incidence of catastrophic costs (43% vs 25%, P =
0.006) and a higher proportion of patients who loaned
money (38% vs 22%, P = 0.014) and sold property (15% vs
6%, P = 0.029). A more substantial proportion also suf-
fered from moderate to severe financial problems (54% vs
38%, P = 0.030). Conversely, in MDR-TB-affected house-
holds, these economic impacts did not differ significantly
between poor and non-poor households.
Before diagnosis, more than three-quarters of all pa-
tients had an income-earning job. Among them, TB and
Table 1 Socioeconomic impact on patients due to TB
Socioeconomic impacts TB MDR-TB P**
Total (%) Poor (%) Non Poor (%) P* Total (%) Poor (%) Non Poor (%) P*
n = 282 n = 175 n = 107 n = 64 n = 23 n = 41
Household experiencing catastrophic costs 102 (36) 75 (43) 27 (25) 0.006 53 (83) 19 (83) 34 (83) 1.000 < 0.001
Perceived impact on financial capacitya
No problem 96 (34) 51 (29) 45 (42) 5 (8) 0 (0) 5 (12)
Slight problem 50 (18) 29 (17) 21 (20) 9 (14) 3 (13) 6 (15)
Moderate problem 58 (21) 42 (24) 16 (15) 13 (20) 5 (22) 8 (20)
Serious problem 48 (17) 32 (18) 16 (15) 20 (31) 7 (30) 13 (32)
Severe problem 30 (11) 21 (12) 9 (8) 17 (27) 8 (35) 9 (22)
Perceived impact on financial capacityb
No problem to slight problem 146 (52) 80 (46) 66 (62) 0.030 14 (22) 3 (13) 11 (27) 0.201 0.009
Moderate to severe problem 136 (48) 95 (54) 41 (38) 50 (78) 20 (87) 30 (73)
Coping strategy
Loaning money 91 (32) 67 (38) 24 (22) 0.014 32 (50) 14 (61) 18 (44) 0.193 0.042
Selling property 33 (12) 27 (15) 6 (6) 0.029 18 (28) 5 (22) 13 (32) 0.395 0.008
Having an income-earning job 201 (71) 119 (68) 82 (77) 0.139 49 (77) 17 (74) 32 (78) 0.708 0.477
n = 201 n = 119 n = 82 n = 201 n = 119 n = 82
Impact on job and income
Job loss 64 (32) 38 (32) 26 (32) 0.801 34 (69) 10 (59) 24 (75) 0.242 0.001
Sick leave 6 (3) 4 (3) 2 (2) 1.000 2 (4) 1 (6) 1 (3) 1.000 0.657
Income loss 122 (61) 78 (66) 44 (54) 0.117 42 (86) 12 (71) 30 (94) 0.041 0.011
% reduction in median (IQR) of patient’s
previous income, %c
40 (100) 50 (0) 18 (100) 0.197 100 (54) 100 (100) 100 (0) 0.091 0.002
% reduction in median (IQR) of household’s
previous income, %c
20 (55) 29 (67) 8 (44) 0.250 40 (38) 27 (72) 42 (27) 0.924 0.299
aPerceived impacts in five categories: no problem, slight problem, moderate problem, serious problem, and severe problem, b Perceived impacts in combined
categories: no problem to slight problem and moderate to severe problem, c Calculated for patients reporting income loss. * P-values indicate the statistical
significance of differences between poor and non-poor households. ** P-values indicate the statistical significance of differences between TB and MDR-TB groups
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MDR-TB caused a high rate of job loss, which was
higher in MDR-TB patients than in TB patients (69% vs
32%, P = 0.001). In addition to job loss, TB also caused
income loss: although some patients maintained their
jobs after diagnosis, their income decreased. The propor-
tion of patients who lost income was much higher than
the proportion who experienced job loss, and was higher
among MDR-TB patients than among TB patients (86%
vs 61%, P = 0.011).
The extent of income loss among patients who had
had an income-earning job before diagnosis was sub-
stantial in both relative and absolute terms. Relative in-
come loss was very high among MDR-TB patients
(median of 100% [IQR 54%]) and was significantly higher
than among TB patients (P = 0.002). Patient’s income
loss subsequently reduced household income (median of
40% [IQR 38%] in MDR-TB and 20% [IQR 55%] in TB
patients, P = 0.299). While the point estimates of relative
income loss suggest that the loss was much higher
among poor TB patients than among non-poor TB ones,
the difference was not significantly different.
Absolute loss (in USD) in patient’s monthly income
was higher in non-poor households than in poor house-
holds, both in the TB (P-value for difference poor and
non-poor: < 0.001) and MDR-TB group (P = 0.004)
(Fig. 1). Household income loss was also greater in
non-poor households than in poor households, both in
the TB (P < 0.001) and MDR-TB group (P = 0.005).
Patients’ perceived needs for social protection
Most patients (84% of TB patients and 80% of MDR-TB
patients) did not know existing social-protection
schemes (Table 2). Even 81% of patients who had health
insurance did not know what social protection was and
were unable to name existing social-protection schemes.
Knowledge of existing schemes did not differ signifi-
cantly between TB and MDR-TB patients (P = 0.794), or
between those with and without health insurance (P=0.112).
The forms of social protection that were most com-
monly named by those who knew of such schemes
were government aid for poor people (in general) and
government aid for healthcare.
After it had been explained what social protection
was, most patients perceived that they needed social
protection. The perceived need was higher among
MDR-TB patients than among TB patients (95% vs 73%,
P = 0.004). Perceived need did not differ significantly be-
tween poor and non-poor patients in either the TB
group (75% vs 70%, P = 0.334) or the MDR-TB group
(100% vs 93%, P = 0.547).
TB and MDR-TB patients all indicated that the three
cost items that most needed to be covered were income
loss (indicated by 24% of TB patients and 34% of
MDR-TB patients); transportation costs (19 and 42%);
and costs for food supplements (15 and 8%) (Table 3).
Patients who reported that they required financial sup-
port were asked about the value of support they needed.
As the wide interquartile ranges show, the value of fi-
nancial support required varied strongly per cost item.
MDR-TB patients perceived a need for a much higher
value of financial support per month for their income
loss than TB patients (median of USD 205 [IQR 121] vs
USD 75 (IQR 112), P < 0.001). However, with regard to
transportation costs per treatment visit and food-supple-
ment costs per month, the values of the financial sup-
port required did not differ between the groups. Among
MDR-TB patients, the values of the financial support
needed did not differ between poor and non-poor
households. But in the TB group, non-poor households
perceived a need for a slightly higher value of financial
support for income loss, transportation, and food sup-
plements (P < 0.001).
The needs perceived by patients who indicated that they
needed financial support were compared with the actual
costs incurred by all patients. For income loss, we
compared the value of perceived needs with the actual
income loss suffered by (a) patients who had experienced
job loss after diagnosis and (b) patients who had
experienced any income loss due to TB regardless of
whether or not they had experienced job loss. Among TB
patients, the median value of the perceived need for
financial support to cover income loss was lower than the
actual costs. Conversely, among MDR-TB patients, the
perceived value of financial support was higher than their
actual costs. For transportation and food-supplement
costs, we compared the value of perceived needs with the
costs actually incurred by all patients. The values of finan-
cial support needed for these two cost items among pa-
tients who expressed the need for support were higher
than the actual median costs among all patients.
Effect of financial support on the incidence of
catastrophic costs
In our simulated scenarios, we used the median values
of the financial support required (see Table 3) to
determine the value of cash transfers. The value of the
cash transfer for transportation costs used in the
simulations was USD 4 per visit. Due to differences in
the number of visits per month, this suggests that the
hypothetical monthly transfer for transportation costs
would vary according to treatment regimen and
treatment phase (intensive and continuation phase). For
TB patients undergoing Category I treatment, the
average number of visit was 4 visit per month during
intensive phase and one visit per month during
continuation phase. These resulted in the average value
of the monthly cash transfer of USD 16 in the intensive
phase and USD 4 in the continuation phase. For TB
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patients undergoing Category II treatment, with daily
visit during intensive phase, the average value of the
monthly cash transfer would be USD 120 in the
intensive phase and USD 4 in the continuation phase.
For MDR-TB patients, the average value of the monthly
cash transfer for transportation would be USD 120 in
both the intensive and continuation phases. The value of
the cash transfer used in the simulations for food sup-
plements was USD 22 per month, both for TB and
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Fig. 1 Patient and household income in (a) TB and (b) MDR-TB-affected households. Pre: income before TB diagnosis. Post: income after TB
diagnosis. P-values above the bar charts indicates the statistical significance of the absolute difference in income loss between poor and non-
poor households. Per bar, red rhombs indicate the mean value of income, upper horizontal lines indicate the q75 value, middle horizontal lines
indicate the median value, and lower horizontal lines indicate the q25 value. MDR-TB: Multidrug-resistant tuberculosis; TB: Tuberculosis
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transfer used in the simulations was USD 75 per month
for TB patients and USD 205 per month for MDR-TB
patients.
If TB-affected households were given support for
transportation, food supplements and income loss
(Scenario VIII), the incidence of catastrophic costs
would be reduced by 25 percentage points, from 36 to
11% (Table 4). This scenario would have the greatest ef-
fects on reducing the incidence of catastrophic costs
than any other scenario, reducing it by 17 percentage
points if patients received only 60% of the potential cash
transfer (Additional file 2: Supplement 1). In this sce-
nario, total median costs for TB patients would be re-
duced from USD 133 (IQR 522) to USD 0 (IQR 106)
(results not reported in the table). Even so, catastrophic
costs would still be faced by 11% of TB-affected house-
holds (95% confidence interval [CI] 8–15%). Among TB
patients who still faced catastrophic costs after cash
transfer, the total median costs would be reduced from
USD 1527 (IQR 1023) to USD 910 (IQR 662).
Although having lower effects than Scenario VIII,
cash-transfer modalities for two cost items (Scenarios VI
and VII) would substantially reduce the incidence of cata-
strophic costs: between these two scenarios, there was no
significant difference (Additional file 2: Supplement 2). Of
the cash-transfer modalities that would provide support
for one cost item, Scenario V would provide the most sub-
stantial effect. Other modalities of providing support for
one cost item (Scenarios II-IV) would provide much
smaller effects than Scenario VIII (P < 0.001). Between
Scenarios II-IV, there were no significant differences.
In the MDR-TB group, cash transfers for transporta-
tion, food supplements and income loss (Scenario VIII)
would reduce the incidence of catastrophic costs by 60
percentage points, from 83 to 23%. Of all the scenarios,
Scenario VIII would have the greatest effect on reducing
the incidence of catastrophic costs. Under Scenario VIII,
median total costs for MDR-TB patients would decrease
from USD 2804 (IQR 3317) to USD 0 (IQR 801).
Twenty-three percent of MDR-TB-affected households
would nonetheless face catastrophic costs after the
transfer (95% CI: 13–35%). Under the same scenario,
median total costs for MDR-TB patients who still faced
catastrophic costs after cash transfer would be reduced
from USD 5606 (IQR 4430) to USD 2613 (IQR 3442).
Using the above cash-transfer values for each scenario,
we estimated the average budget required per patient for
the full duration of treatment under a social-protection
program (Table 4, Fig. 2) Scenario VIII would produce
the most significant effect, but would also require the
highest average budget per patient. For the MDR-TB
group, the effect and the average budget of Scenario VI
were only slightly smaller than those of Scenario VIII.
Other scenarios would produce a much lower effect for
a much lower average budget.
In the TB group, cash transfers would reduce the
incidence of catastrophic costs to a much greater extent in
poor households than in non-poor households (Fig. 3). In
Scenarios V-VIII, the gap between poor and non-poor
households would disappear. A sensitivity analysis showed
that the gap would also disappear under Scenarios V-VIII
if patients received only 60–90% of the cash transfers
(Additional file 2: Supplement 3 and Supplement 4).
In the MDR-TB group, the incidence of catastrophic
costs at baseline was equally high in the poor and non-poor
households. With most scenarios, the impact was similar
for poor and non-poor MDR-TB households. Only cash
transfers for transportation costs (Scenario II) would pro-
duce a significantly lower incidence of catastrophic costs
among poor households than among non-poor ones.
Discussion
Our results suggest that current levels of social protection
in Indonesia are not enough to mitigate the socioeconomic
impacts of TB, which include a high incidence of
catastrophic costs, high rates of job and income loss, and a
high proportion of patients who have to borrow money and
sell their property. Due to these enormous impacts, TB
Table 2 TB and MDR-TB patients’ knowledge of social-protection schemes
Knowledge of existing social-protection scheme Type of TB P-value Having insurance P-value
TB (%) MDR-TB (%) Yes (%) No (%)
Did not know what social protection was 236 (84) 51 (80) 0.794 187 (81) 100 (88) 0.112
Knew and could name the following social-protection schemes: 46 (16) 13 (20) 45 (19) 14 (12)
Government aid for poor people (in general) 19 (7) 4 (6) 19 (8) 4 (4)
Government aid for healthcare 13 (5) 2 (3) 11 (5) 4 (4)
Direct government aid, cash transfera 11 (4) 1 (2) 9 (4) 3 (3)
Government aid for transportation costs 0 (0) 3 (5) 3 (1) 0 (0)
Government aid for education 1 (0) 2 (3) 2 (1) 1 (1)
Other government aid 0 (0) 1 (2) 0 (0) 1 (1)
aknown as Bantuan Langsung Tunai in Indonesian Bahasa
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patients urgently need social protection, mainly to
cover the three costs they had indicated as most
important: income loss, transportation costs, and
food-supplement costs. In our simulations, the inci-
dence of catastrophic costs were substantially reduced
by a hypothetical scenario (Scenario VIII) that pro-
vided financial support for these three cost items.
Nevertheless, a financial support system in which pa-
tients received fixed amounts of money for income
loss, transport and food-supplement costs would not
be able to reduce the incidence of catastrophic costs
to 0 %, the target set by the WHO.
Our findings suggest that future policies should not
rely on cash transfers for only one cost item. Although
cash transfers to cover patient income loss can make a
substantial contribution to reducing catastrophic costs, a
single cash transfer of the sort examined in our study
would not be enough to eliminate catastrophic costs.
The existing types of support that patients may currently
receive are equally inadequate; these mainly cover direct
non-medical costs, such as food or nutritional supple-
ment packages and travel vouchers from either govern-
ment or international donors [21, 24, 25]. The impacts
of financial support would be greater if cash transfers
Table 3 Perceived needs for financial support for each cost item and their actual costs, median (IQR), in USD
Cost items Perceived needsa Actual costsb













TB n = 282 n = 175 n = 107
Income loss, per
month
68 (24) 75 (112) 40 (23) 75 (112) 28 (26) 75 (131) <
0.001
86 (127)c 75 (77)c 149 (185)c
75 (112)d 61 (87)d 142 (174)d
Transportation, per
visit
54 (19) 4 (5) 42 (24) 2 (2) 12 (11) 7 (17) <
0.001
0 (1) 1 (1) 0 (0)
Food-supplement,
per month
42 (15) 22 (37) 24 (14) 22 (21) 18 (17) 34 (60) <
0.001
2 (11) 1 (9) 3 (15)
Consultation, per visit 11 (4) 13 (19) 6 (3) 10 (21) 5 (5) 22 (26) <
0.001
0 (0) 0 (0) 0 (0)
Drugs, per month 11 (4) 15 (33) 8 (5) 10 (15) 3 (3) 37 (4) 0.188 0 (0) 0 (0) 0 (0)
Food, per visit 3 (1) 4 (3) 2 (1) 2 (3) 1 (1) 7 (0) 0.477 0 (0) 0 (0) 0 (0)
Other disease(s),
per visit
1 (0) 7 (0) 1 (1) 7 (0) 0 (0) N/A N/A N/Ae N/Ae N/Ae
Guardian, per visit 1 (0) 7 (0) 1 (1) 7 (0) 0 (0) N/A N/A 0 (0) 0 (0) 0 (0)
MDR-TB n = 64 n = 23 n = 41
Income loss,
per month
22 (34) 205 (121) 6 (26) 176 (80) 16 (39) 224 (174) 0.367 183 (105)c 149 (191)c 205 (149)c
176 (114)d 123 (180)d 183 (149)d
Transportation, per visit 27 (42) 4 (11) 10 (43) 3 (13) 17 (41) 4 (8) 0.223 1 (2) 1 (2) 1 (2)
Food-supplements,
per month
5 (8) 22 (34) 3 (13) 30 (26) 2 (5) 19 (7) 0.200 15 (29) 15 (30) 15 (24)
Consultation, per visit 0 (0) N/A 0 (0) N/A 0 (0) N/A N/A 0 (0) 0 (0) 0 (0)
Drug, per month 0 (0) N/A 0 (0) N/A 0 (0) N/A N/A 0 (0) 0 (0) 0 (0)
Food, per visit 3 (5) 1 (1) 2 (9) 1 (0) 1 (2) 2 (0) 1.000 1 (1) 1 (1) 1 (1)
Other disease(s),
per visit
0 (0) N/A 0 (0) N/A 0 (0) N/A N/A N/Ae N/Ae N/Ae
Guardian, per visit 1 (2) 7 (0) 0 (0) N/A 1 (2) 7 (0) N/A 0 (0) 0 (0) 0 (0)
aThe value of perceived needs for financial support were calculated only on the basis of information provided by those who indicated that they need financial
support for each specific cost item. b Actual costs except for income loss were calculated on the basis of information from all patients; c Actual costs for income
loss were calculated on the basis of information from patients who experienced job loss after diagnosis; d Actual costs for income loss were calculated on the
basis of information from patients who had experienced personal income loss regardless of whether or not they had experienced job loss after diagnosis; N/A,
not applicable; e During the interview, no specific question was asked on actual costs for other diseases; **P-values indicate the statistical significance of
differences regarding the value of perceived needs between poor and non-poor households per cost item
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were provided for a combination of income loss, travel
costs, and food-supplement costs.
Despite their substantial impact on reducing
catastrophic costs, the cash transfers in our scenarios
would not be enough to achieve the WHO’s target of 0
% of households facing catastrophic costs. This failure is
likely to be due to the high variability of costs between
patients, and particularly of the cost due to income loss,
which was the greatest component of the total costs
incurred due to TB. Actual monthly income losses were
also higher than the cash transfers simulated in our
hypothetical scenarios. For example, while the transfer
was set at USD 75 per month, actual median monthly
income loss among TB patients who experienced job
loss was USD 75 (IQR 77) for poor patients, and USD
149 (IQR 185) for non-poor patients.
As actual costs and the perceived needs for financial
support vary greatly between patients, it is difficult to
determine the value of any cash transfer to be delivered.
We based the value of cash transfers on the median
value of patients’ perceived needs. Although the median
value of cash transfer to cover transportation and
food-supplement costs was higher than the median value
of their actual costs, the actual value of transport and
food supplements latter was sometimes higher than the
cash transfer. The transfer in these cases did not cover
the actual costs. However, the cash transfers simulated
in our study would increase the NTP budget per capita
by between approximately 46% (Scenario II) and 148%
(Scenario VIII) for TB patients, and by between approxi-
mately 8% (Scenario II) and 20% (Scenario VIII) for
MDR-TB patients [26]. While increasing the value of the
cash transfers might be effective in terms of further re-
ducing catastrophic costs, its affordability and sustain-
ability should be carefully considered.
A way of reducing the incidence of catastrophic costs
more effectively might be to target the financial support to
those patients most likely to experience catastrophic
expenditures. The targeting system could differ between
settings, and could use various criteria to identify patients
who need financial support [14]. Such criteria might
include the determinants of catastrophic costs, such as
household poverty level, job status before and after
diagnosis, breadwinner status in the family, having had
previous TB treatment, and experiencing adverse effects
[6]. The disadvantages of such an approach would include
the risks of greater stigmatization and of the greater
bureaucracy needed to manage the targeting system, and
may also prompt patients to pretend to remain sick in
order to keep their entitlement to financial support [14, 24].
Our findings stress that the WHO’s target of
eliminating the incidence of catastrophic costs requires
Table 4 The incidence of catastrophic costs in eight hypothetical scenarios
Simulated hypothetical scenario Incidence of catastrophic costs Average budget per patient for full
duration of treatment, in USD
% (95% CI) Mean (95% CI)
TB
I Baseline (no cash transfer) 36 (31–42) –
II Transportation costs 28 (23–33) 114 (100–127)
III Food-supplement costs 26 (21–30) 143 (141–145)
IV Income lossa 26 (21–30) 110 (88–134)
V Income lossb 17 (13–21) 210 (183–236)
VI Transportation costs and income loss 17 (13–22) 224 (197–253)
VII Food-supplement costs and income loss 16 (12–20) 253 (231–278)
VIII Transportation, food supplement, and income loss 11 (8–15) 367 (338–398)
MDR-TB
I Baseline (no cash transfer) 83 (73–92) –
II Transportation costs 59 (47–71) 1337 (1327–1344)
III Food-supplement costs 77 (65–87) 269 (269–269)
IV Income lossa 58 (46–70) 1309 (1010–1617)
V Income lossb 52 (39–65) 1617 (1338–1899)
VI Transportation costs and income loss 28 (18–40) 2647 (2351–2958)
VII Food-supplement costs and income loss 53 (41–66) 1578 (1279–1886)
VIII Transportation, food supplement, and income loss 23 (13–35) 2916 (2620–3227)
aThe hypothetical cash transfer was assumed to have been delivered to TB patients who had experienced job loss, bThe hypothetical cash transfer was assumed
to have been delivered to TB patients who had experienced any income loss regardless of whether or not they had experienced job loss
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innovations in social-protection programs. If this object-
ive is to be attained, a combination of strategies will be
required to reduce the costs patients incur in the trajec-
tory between the pre-diagnostic phase and the end of
treatment. To reduce medical costs in the pre-diagnostic
and diagnostic phases, TB service delivery under the
NTP – which currently provides free TB treatment in
NTP-linked health services only after diagnosis – should
be fully integrated into the national health insurance
scheme. In turn, such integration would speed up diag-
nostic procedures and improve access to TB treatment,
possibly reducing transport costs and potentially even
income loss. However, as the proportion of costs in-
curred in this phase is much smaller than the proportion
of costs in the treatment phase [6], the strategy would
have limited impact on total cost reduction. The strategy
should therefore be combined with strategies for pre-
venting socioeconomic impacts in the treatment phase
of TB.
Since income loss was the greatest cost in the
treatment phase, income loss must be limited by
preventing unnecessary job loss. In the formal sector,
this could be done by strengthening job-security policies
so as to avoid the dismissal of workers with TB and
MDR-TB. In the informal sector, resolving the problem
of income loss would be more of a challenge. Whatever
the case, it is important to design a legal framework that
provides additional social protection, not only to com-
pensate patient’s income loss, but also to prevent further
severe TB-related socioeconomic impact by ensuring
that patients are covered by national health insurance.
Another possible way of reducing treatment costs is to
shorten the TB treatment period [15, 27]. The
development of a new TB drug regimen with a shorter
treatment period is currently being evaluated [28].
Positive evidence that this shorter period is just as
cost-effective would allow a reduction in direct
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Fig. 2 The remaining incidence of catastrophic costs and the average budget per patient for each scenario in (a) the TB group and (b) the MDR-
TB group. Vertical lines in each colored circle are standard errors of the incidence of catastrophic costs. Horizontal lines in each colored circle are
standard errors of the average budget per patient. MDR-TB: Multidrug-resistant tuberculosis; TB: Tuberculosis
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likelihood of catastrophic costs [29]. For patients with
MDR-TB, a possible way of reducing transportation
costs and possible income loss is to increase the number
of MDR-TB drug-delivery centres.
Unfortunately, the strategies for eliminating catastrophic
costs named above would require considerable resources,
while most of the TB high-burden countries are low- to
middle-income countries with limited resources for
social-protection policies [3]. If global action to combat TB
does not become more innovative and is not given more
funding, such countries will be left with very little chance
of attaining the target stipulated in the WHO’s 2020 and
2025 milestones of 0 % of families that face catastrophic
costs.
The limitations of this study fall into two main
categories. First, we enrolled only TB and MDR-TB pa-
tients who had been treated in public health services, and
thus not in the private sector. We did not interview
patients who had dropped out of treatment, and we ex-
cluded any TB patients or suspected TB patients who had
not followed standard TB diagnostic and treatment proce-
dures. Similarly, the only MDR-TB patients we interviewed
were those who had been treated in a national pulmonary
referral hospital in an urban area (Jakarta). With regard to
the extent of patients’ needs for social protection and to
the value of cash transfers, these strict inclusion criteria
may have led us to underestimate the needs of TB patients
and to overestimate the needs of MDR-TB patients.
MDR-TB patients treated in other MDR-TB centres or re-
ferred to PHCs after culture conversion may have lower
direct non-medical costs, and may thus have lower re-
quirements with regard to social protection.
Secondly, while these findings may apply to the island
of Java, which constitutes 60% of the Indonesian
population [30], they may not apply directly to the










































































Fig. 3 The incidence of catastrophic costs in poor and non-poor households in (a) TB and (b) MDR-TB-affected households. P-values indicate the
differences per scenario between poor and non-poor households. MDR-TB: Multidrug-resistant tuberculosis; TB: Tuberculosis
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travel costs may be much higher than in Java, and where
income loss may be much lower. It is also uncertain
whether these findings will apply to other TB
high-burden countries with a low- to middle-income.
Conclusions
Indonesia’s current level of social protection is not
sufficient to mitigate the socioeconomic impact of TB.
Financial support for income loss, transportation costs,
and food-supplement costs will substantially reduce the
incidence of catastrophic costs, but financial support
alone will not be sufficient to achieve the target of 0%
TB-affected households facing catastrophic costs. This
would require innovative social-protection policies and
higher levels of domestic and external funding.
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